High radiation dose in chemoradiotherapy followed by immunotherapy with durvalumab in patients with stage III non-small cell lung cancer does not increase risk for pneumonitis
Research output: Journal article (peer-reviewed) › Journal article
Fingerprint
Dive into the research topics of 'High radiation dose in chemoradiotherapy followed by immunotherapy with durvalumab in patients with stage III non-small cell lung cancer does not increase risk for pneumonitis'. Together they form a unique fingerprint.